Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock is trading at $22.09, up 3.66%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TEVA shares have gain 33.88% over the last week, with a monthly amount glided 29.71%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] stock has seen the most recent analyst activity on July 10, 2024, when Argus upgraded its rating to a Buy but kept the price target unchanged to $20 for it. Previously, JP Morgan upgraded its rating to Neutral on March 08, 2024, and kept the price target unchanged to $14. On February 12, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $19 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $14 on January 23, 2024. Piper Sandler upgraded its rating to a Neutral and raised its price target to $12 on January 03, 2024. HSBC Securities started tracking with a Buy rating for this stock on December 18, 2023, and assigned it a price target of $13. In a note dated November 27, 2023, UBS upgraded an Buy rating on this stock and boosted its target price from $11 to $13.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock has fluctuated between $10.34 and $21.98 over the past year. Currently, Wall Street analysts expect the stock to reach $24.2 within the next 12 months. Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] shares were valued at $22.09 at the most recent close of the market. An investor can expect a potential return of 9.55% based on the average TEVA price forecast.
Analyzing the TEVA fundamentals
Teva- Pharmaceutical Industries Ltd. ADR [NYSE:TEVA] reported sales of 16.81B for the trailing twelve months, which represents a growth of 13.40%. Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.15 and Total Capital is 0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 3.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.41 points at the first support level, and at 20.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.47, and for the 2nd resistance point, it is at 22.85.
Ratios To Look Out For
For context, Teva- Pharmaceutical Industries Ltd. ADR’s Current Ratio is 0.89. Also, the Quick Ratio is 0.61, while the Cash Ratio stands at 0.24. Considering the valuation of this stock, the price to sales ratio is 1.49, the price to book ratio is 4.13.
Transactions by insiders
Recent insider trading involved Bridger Management, LLC (1), Shareholder, that happened on Dec 20 ’24 when 0.29 million shares were purchased. EVP, Head of U.S. Commercial, Fox Christine completed a deal on Nov 20 ’24 to sell 19388.0 shares. Meanwhile, Officer Fox Christine bought 19388.0 shares on Nov 20 ’24.
